Short answer: It can improve pricing visibility and control, but it adds coordination work. Before carving out, confirm the TPA allows it, that deductibles and out-of-pocket maximums will accumulate across both vendors, that stop-loss covers the PBM’s claims, and that net savings hold up after fees.
A carve-in bundles the drug benefit with the medical TPA or carrier; a carve-out contracts a standalone PBM. Some carrier ASO arrangements price their medical services assuming their own PBM is used, so get both options quoted.
Checklist for a carve-out:
- Accumulator sharing so employees’ deductible and out-of-pocket maximum count both medical and drug spending.
- Stop-loss: pharmacy claims included under specific and aggregate coverage, with matching incurred and paid definitions.
- Data feeds for RxDC reporting, gag clause compliance and claims analysis.
- The PBM’s compensation disclosure and the contract’s rebate, spread and audit terms.
- Member disruption: formulary changes, specialty pharmacy, prior authorizations in progress.
Specialty drugs and GLP-1 medications often drive the decision; model them with the group’s actual claims.